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Abstract:
Aim: To determine the in-vitro activity of
linezolid in methicillin resistant Staphylococ-
cus aureus. Material and Methods: Samples
such as pus, sputum, ear swab, pleural fluid that
were received in microbiology laboratory were
included in the study. Gram staining was per-
formed on all the samples. Smears showing
gram positive cocci in clusters were consid-
ered.  100 strains of Staphylococci were sub-
sequently processed and identified using stan-
dard microbiological methods.  Staphylococ-
cus aureus so identified  were subjected to
screening for methicillin resistance using ox-
acillin disc (1µgm) and also in-vitro activity of
linezolid by Kirby-Bauer disc diffusion
method. Subsequently minimum inhibitory con-
centration for linezolid was determined by E
test using Hi-Comb strips obtained from Hi-
Media. Results: Out of 100 strains of Staphy-
lococcus aureus isolated, 42 (42%) were me-
thicillin resistant and 58 (58%) were methicil-
lin sensitive. Majority of methicillin resistant
Staphylococcus aureus isolated were from pus
(35) followed by sputum (7). Among the 42
strains of methicillin resistant Staphylococcus
aureus  isolated, sensitivity to linezolid
(30mcg) was 87.71% and minimum inhibitory
concentration was in the range of 0.1 - 1µgm/ml.
Conclusion: Linezolid is a novel alternative
drug to vancomycin in the treatment of severe
methicillin resistant Staphylococcus aureus
infections.
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Introduction:
Over the last two decades, the increasing inci-
dence of methicillin resistant Staphylococcus
aureus (MRSA) has caused significant clini-
cal concern worldwide. Methicillin resistance
in Staphylococcus aureus is also associated
with resistance to several commonly used an-
timicrobial agents such as the macrolides,
lincosamides, quinolones, trimethoprim-
sulfamethoxazole and aminoglycosides [1].
Such resistance leads to increased mortality and
also decrease in cost-effectiveness of treatment.
Glycopeptide antibiotic vancomycin has been
the drug of choice for the treatment of serious
Staphylococcal infections for the decades with
no resistance emerged until the late 90s.  In
Japan, the transmission within hospitals of
methicillin resistant Staphylococcus aureus
strains with heterogeneous resistance to van-
comycin has been reported [2]. With the in-
creasing incidence of multidrug resistant Sta-
phylococci and emergence of resistance to gly-
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copeptides in methicillin resistant Staphylo-
coccus aureus,  therapeutic options have be-
come increasingly limited. Thus there is a clear
need for novel agents as alternatives in the treat-
ment of infections caused by methicillin resis-
tant Staphylococcus aureus [3].
The only available antimicrobial with proved
high activity against multi-resistant Staphylo-
coccus aureus, including strains with reduced
susceptibility to glycopeptides is linezolid. So
this study was undertaken to determine the in-
vitro activity of linezolid in methicillin resis-
tant Staphylococcus aureus  infections.
Material and Methods:
The study was carried out among the patients
attending BLDEUS Shri B. M. Patil Medical
College Hospital, Bijapur, Karnataka. Samples
such as pus, sputum, ear swabs, pleural fluid that
were received in microbiology laboratory were
included in the study. Gram staining was per-
formed on all the samples. Smears showing
gram positive cocci in clusters were consid-
ered.  100 strains of Staphylococci were sub-
sequently processed. The samples were inocu-
lated on blood agar, nutrient agar, Mac-conkeys
agar, then incubated overnight at 370C. Staphy-
lococcus aureus was identified based on the
colony morphology, gram staining, tube coagu-
late test, slide coagulate test, phosphatase test,
deoxyribonuclease test and mannitol fermen-
tation test, by using standard methods.
All the confirmed Staphylococcus aureus
strains were subsequently tested for methicil-
lin resistance by Kirby-Bauer disc diffusion
method using oxacillin discs (1µgm/disc) ob-
tained from Hi- Media laboratories and the
medium used was Mueller-Hinton agar with 4%
sodium chloride. The plates were incubated at
350C for 24 hrs and zone size was recorded.
The isolates were considered resistant if the
zone of inhibition was 10mm or less [4].
Subsequently in-vitro activity for linezolid was
tested by Kirby-Bauer disc diffusion method
on Mueller-Hinton agar using linezolid disc
(30mcg) obtained from Hi-Media laboratories.
Minimum inhibitory concentration for
linezolid was found out by E-test on Mueller-
Hinton agar using Hi-Comb strips obtained
from Hi-Media laboratories. The E test was
performed according to the protocol supplied
by the manufacturer and minimum inhibitory
concentration was calculated as the value at
which the zone of inhibition converged on the
comb like projection of the strip [5].  Mini-
mum inhibitory concentration within a range of
< 2µg/ml for the concentration gradients rang-
ing between 8 0.001µg was taken as sensitive.
Results:
Out of 100 strains of Staphylococcus aureus
isolated 42(42%) showed resistance to methi-
cillin (methicillin resistant Staphylococcus
aureus) and 58(58%) were sensitive (methi-
cillin sensitive Staphylococcus aureus). Ma-
jority of methicillin resistant Staphylococcus
aureus isolated were from pus (35), followed
by Sputum (7). Among the 42 methicillin re-
sistant Staphylococcus aureus isolates, sensi-
tivity to linezolid (30mcg) was 87.71% by
Kirby-Bauer disc  diffusion method and mini-
mum inhibitory concentration was in the range
of 0.1-1µg/ml.
Discussion:
Staphylococcus aureus is a major cause of
nosocomial infections including pneumonia,
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post-operative wound infections, bacteremia
and other infections. Over past 50 years Sta-
phylococcus aureus has acquired resistance to
all the previously effective antimicrobials, and
has today emerged as one of the most impor-
tant nosocomial pathogen [6]. Vancomycin re-
mains the drug of choice in the treatment of
these infections, but vancomycin has potential
for toxic side effects like renal impairment
besides its prohibitive cost. Concerns about its
reduced effectiveness and development of re-
sistance are mounting [7]. So this study was
carried out to detect the efficiency of a novel
drug linezolid in the treatment of methicillin
resistant Staphylococcus aureus infections
which could be effective if vancomycin fails.
Linezolid belongs to a new synthetic class of
antimicrobials, the oxazolidinones. They are
active against a wide variety of gram positive
organisms including methicillin resistant Sta-
phylococcus aureus .  Linezolid binds the 50S
ribosomal subunit and inhibits bacterial protein
synthesis by interfering with the formation of
initiation complex in bacterial translation sys-
tems. Because this agent possesses a novel
structure and unique mechanism of action, it
does not display cross resistance with other
classes of antimicrobial agents [3].  Linezolid
has an acceptable safety profile for both intra-
venous and oral administration and has proven
to be effective in the treatment of infections
due to methicillin resistant Staphylococcus
aureus in critically ill patients [8].  Side ef-
fects to linezolid have been mostly pain in ab-
domen and hematological adverse events.
Linezolid also helps in diabetics when vanco-
mycin fails [9].
In the present study the sensitivity of methicil-
lin resistant Staphylococcus aureus  to
linezolid has been 87.71% by Kirby- Bauer disc
diffusion method and minimum inhibitory con-
centration has been in the range of 0.1-1µg/ml.
All the patients receiving linezolid have had full
recovery as shown by negative follow up cul-
tures. These findings suggest that linezolid
could be as effective as vancomycin in the treat-
ment of methicillin resistant Staphylococcus
aureus   infections and may be more effective
than vancomycin in achieving the microbiologi-
cal eradication. Our results are consistent with
the studies of Carmen Betriu et al [3]. and
Srinivasan S et al [7]. Thus linezolid is a prom-
ising therapeutic option in the era of rapidly
growing antibiotic resistance due to its cost ef-
fectiveness and comparatively lower side ef-
fects.
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